Navigation Links
FDA Issues Complete Response Letter for Lorcaserin New Drug Application
Date:10/23/2010

SAN DIEGO and WOODCLIFF LAKE, N.J., Oct. 23, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) and Eisai Inc. announced that the US Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding Arena's New Drug Application (NDA) for lorcaserin. Lorcaserin is intended for weight management, including weight loss and maintenance of weight loss, in patients who are obese (Body Mass Index, or BMI, >/= 30) or patients who are overweight (BMI >/= 27) and have at least one weight-related co-morbid condition.

The FDA has completed its review of the NDA and determined that it cannot approve the application in its present form. In the CRL, the FDA outlined the non-clinical and clinical reasons for their decision.

The non-clinical issues identified by the FDA included diagnostic uncertainty in the classification of mammary masses in female rats, unresolved exposure-response relationship for lorcaserin-emergent mammary adenocarcinoma, and unidentified mode of action and unclear safety margin for lorcaserin-emergent brain astrocytoma.

The CRL included the following requests related to the non-clinical issues: provide a detailed accounting of all slides prepared from female rats that contributed to mammary tumor incidence data in each update to the FDA and to the final study report; in consultation with the FDA, identify an independent pathologist or group of pathologists to re-adjudicate all mammary and lung tissues (neoplastic and nonneoplastic lesions) from all female rats; demonstrate that the apparent increase in aggressiveness of adenocarcinoma in rats administered lorcaserin is reasonably irrelevant to human risk assessment; and provide additional data/information regarding the distribution of lorcaserin to the CNS in animals and human subjects that would clarify or provide a better estimate of astrocytoma exposure
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Actavis Inc. Issues a Voluntary Recall of 18 Lots of Fentanyl Transdermal System 25 mcg/h
2. FDA Issues Warnings to Marketers of Unapproved Chelation Products
3. Cannabis Science Issues Guidance on Its Progress Toward FDA Investigative New Drug Applications For Clinical Trials and Proposed Dividend Payout for Current Shareholders to Receive a New Class of Common Stock
4. Medical Technology, Funding & Government Experts Address Business, Investment, Reimbursement, Compliance, Innovation, Regulatory and Legal Issues at AdvaMed 2010
5. Prevent Blindness America Issues Call-to-Action to Make UV Eye Protection a National Health Priority
6. FDA Issues New Dosing Guide for Children Using Valcyte
7. New Insights Provide Promise for Development of Tools to Protect Damaged Tissues
8. New Hope in Austin, Texas for Children Dealing with Social, Academic and Behavioral Issues; Austin Brain Balance Achievement Centers Grand Opening to Include Lectures for Parents, Teachers and Health Professionals
9. Medco Issues $1.0 Billion of Senior Notes
10. FDA Issues Assessments of the 510(k) Program and Use of Science in Decision-Making
11. China Sky One Medicals Chief Financial Officers Health Issues to Restrict His Availability to Investors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014 Leading events organizer UBM ... for the seventh year to São Paulo, Brazil ... August 2014. The event will co-locate with Food Ingredients South ... comprehensive meeting point for the pharmaceutical industry.      ... for pharmaceutical sales are now exploring the South ...
(Date:7/25/2014)... BOHEMIA, N.Y. , July 25, 2014 /PRNewswire-iReach/ -- Dr. ... Pediatrics clinic, GPM Pediatrics, reacts to a recent study, ... adulthood. Photo - http://photos.prnewswire.com/prnh/20140723/129709 ... mothers exposed to severe stress are more likely than others ... occurred months before pregnancy." There were two specific ...
(Date:7/24/2014)... , July 24, 2014  PTC Therapeutics, Inc. ... Company will host a webcast conference call to report ... update on the company,s business and outlook on Thursday, ... opening of the market. The call ... (973) 935-8152 (international) five minutes prior to the start ...
Breaking Medicine Technology:CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2
... 24, 2011 Reportlinker.com announces that a new market ... Therapeutics for Immune System Disorders ... the global market for drugs for the treatment of ... The market size is forecast to grow at a ...
... March 24, 2011 Tarsa Therapeutics today announced that ... salmon calcitonin in the treatment of postmenopausal osteoporosis was ...  The results will be used to support a New ... Administration (FDA) targeted for the fourth quarter of 2011, ...
Cached Medicine Technology:Reportlinker Adds Therapeutics for Immune System Disorders 2Reportlinker Adds Therapeutics for Immune System Disorders 3Reportlinker Adds Therapeutics for Immune System Disorders 4Reportlinker Adds Therapeutics for Immune System Disorders 5Reportlinker Adds Therapeutics for Immune System Disorders 6Reportlinker Adds Therapeutics for Immune System Disorders 7Reportlinker Adds Therapeutics for Immune System Disorders 8Reportlinker Adds Therapeutics for Immune System Disorders 9Reportlinker Adds Therapeutics for Immune System Disorders 10Reportlinker Adds Therapeutics for Immune System Disorders 11Reportlinker Adds Therapeutics for Immune System Disorders 12Reportlinker Adds Therapeutics for Immune System Disorders 13Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis 2Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis 3Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis 4
(Date:7/25/2014)... (PRWEB) July 25, 2014 The European ... market in Europe with analysis and forecast of revenue. ... at $ 1007.2 million in 2013, and is estimated ... a CAGR of 9.4 %, from 2013 to 2018. ... chromatography reagents market, to get an idea of the ...
(Date:7/25/2014)... 25, 2014 (HealthDay News) -- Although cervical cancers are ... linked to human papillomavirus (HPV) are increasing, a new ... the base of the tongue and tonsils have increased ... women younger than 45, the Canadian researchers report. ... among younger men and of anal cancer among younger ...
(Date:7/25/2014)... Innerspire, LLC ( http://www.innerspire.com ) announced today ... Creative Enrollment Specialist. In this role, Greg will be ... as his accomplished design skills to further develop Innerspire’s ... service the creative marketing needs of existing ... small business owners and individuals looking to accelerate the ...
(Date:7/25/2014)... 25, 2014 There are 700,000 people in ... each day. Though when someone hears the words, “you have ... unsure of the next step and where to turn. , ... out that next step by providing and pursuing the answers ... Brian Olson, member of the ABTA’s Board of Directors and ...
(Date:7/25/2014)... July 25, 2014 According to the ... Wafer, Devices, Applications, and Geography - Analysis & Forecast ... substrate is expected to reach $3.01 Billion by 2020 ... Technology Market for devices is expected to reach $6.17 ... includes an in-depth analysis of application and geography. , ...
Breaking Medicine News(10 mins):Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Liquid Chromatography Reagents Market is Expected to Reach $1581.8 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Anal, Throat Cancers on the Rise Among Young Adults, Study Finds 2Health News:Innerspire, LLC Continues National Expansion 2Health News:Innerspire, LLC Continues National Expansion 3Health News:Innerspire, LLC Continues National Expansion 4Health News:American Brain Tumor Association Board of Directors Member Shares Story of Brain Tumor Survivorship 2Health News:American Brain Tumor Association Board of Directors Member Shares Story of Brain Tumor Survivorship 3Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 5Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 6
... for Prevention, Mental,Health and Low-Income Programs, Boosted ... Today a minority of,the U.S. Senate ... for the 44 million Americans who depend ... Providers Act, which would have improved,Medicare,s prevention, ...
... Would Have Improved Benefits for Prevention, Mental,Health and ... FE, N.M., June 12 SUMMARY: Today a,minority ... protect and,improve Medicare for the 44 million Americans ... and Providers Act, which would have,improved Medicare,s prevention, ...
... Corporation,(Nasdaq: PODD ), the leader in patch ... announced the Company will participate in,the William Blair ... scheduled to present an overview of the Company ... The Four Seasons Hotel in Chicago, IL., ...
... 12 Benchmark findings from the,study, conducted ... (BEB),suggest that formal management of training program ... one of the key success drivers in,effective ... Download a complimentary excerpt of this member-driven ...
... Senate voted 54,to 39 in favor of S. ... of 2008. However, that did not achieve the ... provisions that provide,prompt payment of Medicare Part D ... reimbursement cuts for generic prescription,drugs. In response Bruce ...
... complaints of insomnia predicted a healthier life, study finds ... is associated with healthy aging, a new study found. ... assessed 2,226 women aged 60 and older for use ... awakening, snoring, overall sleep quality, and sleep duration. Based ...
Cached Medicine News:Health News:AARP Indiana Key Vote News Alert: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 2Health News:AARP Indiana Key Vote News Alert: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 3Health News:AARP NEW MEXICO KEY VOTE NEWS ALERT: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 2Health News:AARP NEW MEXICO KEY VOTE NEWS ALERT: AARP Dismayed by Senate Vote to Block Medicare Improvement Bill 3Health News:Better Sleepers Are 'Successful Agers' 2
... range of automatic systems for performing erythrocyte ... of blood. With the introduction of the ... diagnostic market a truly revolutionary testing system ... associated with the traditional ESR techique.,By means ...
... of automatic systems for performing erythrocyte sedimentation ... blood. With the introduction of the Ves-matic ... market a truly revolutionary testing system which ... with the traditional ESR techique.,By means of ...
... VACUETTE® erythrocyte sedimentation rate analysers, ... The new generation unites the well-established ... whole range of additional innovations which ... erythrocyte sedimentation rate. Cost effectiveness is ...
Blood sedimentation rate analysis...
Medicine Products: